## Supplemental Digital Content; Table 1. Proportion of ocular itching responders after conjunctival allergen challenge: secondary end point (intent-to-treat population)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Olopatadine 0.77% | Olopatadine 0.2% | Olopatadine 0.1% | Vehicle |
| *Onset of action* Number of responders n (%)Difference | 70 (71.4) | 73 (73.7)–2.31 | 59 (59.6)11.83 | 5 (10.2)61.22\* |
| *24 hour*Number of responders n (%)Difference | 40 (40.8) | 30 (30.3)10.51 | 26 (26.3)14.55† | 2 (4.1)36.73\* |

## \**P*<0.0001; †*P*<0.05. CAC, conjunctival allergen challenge. An ocular itching responder was defined as any subject with a score of zero on ocular itching for both eyes, or at least a 2 unit reduction in ocular itching relative to a baseline confirmatory CAC score; scores were averaged across both eyes and over the three post-CAC timepoints. The intent-to-treat population included all randomized subjects who received treatment and had post-conjunctival allergen challenge data